当前位置:首页 > 成功案例 > SIRTEX

SIRTEX


SIRTEX

图片.png

Sirtex是一家全球性的生命科学公司,主要产品为SIR Spheres®Y-90树脂微球,一种针对无法手术的原发性或继发性(转移性)肝肿瘤患者的靶向放射疗法。 Sirtex已向全球50多个国家的1400个中心提供了超过100000SIR Spheres Y-90树脂微球。

Sirtex的愿景是癌症将不再是一种晚期疾病,而是一种患者可以成功地生存的疾病。

在过去的几年里全球Sirtex团队有了长足的发展,目前在20个国家拥有超过266名员工。

Sirtex全球总部位于美国波士顿,欧洲、中东、非洲(EMEA)地区总部位于德国波恩,亚太地区总部位于澳大利亚悉尼。


Sirtex is a global life-sciences company that markets SIR-Spheres® Y-90 resin microspheres, a targeted radiation therapy for patients with inoperable primary or secondary (metastatic) liver tumours. Sirtex has supplied over 100,000 doses of SIR-Spheres Y-90 resin microspheres to 1400 centres in over 50 countries worldwide.

The vision of Sirtex is that cancer will no longer be a terminal disease , but a disease that patients can successfully live with.

The global Sirtex team over the past few years has grown significantly and we now have over 266 employees located in 20 countries.

The Global Head Office of Sirtex is located in Boston, USA, the European, Middle East, African (EMEA) Regional Headquarters is located in Bonn, Germany and the Asia Pacific Regional Headquarters is located in Sydney Australia.  

 

http://www.sirtex.com/au/


0.174148s